27389 Rapid and sustained improvement in itch in children aged 6–11 years with severe atopic dermatitis (AD) treated with dupilumab: Analysis from the LIBERTY AD PEDS phase 3 trial - 07/08/21
Doi : 10.1016/j.jaad.2021.06.576
Le texte complet de cet article est disponible en PDF.
| Commercial Disclosure: Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. Medical writing/editorial assistance: A. Houzelle, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc |
© 2021
Publié par Elsevier Masson SAS.
Vol 85 - N° 3S
P. AB140 - septembre 2021 Retour au numéro
Article précédent
- 27383 Bimekizumab response maintenance up to 1 year in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials
- Andrew Blauvelt, Yayoi Tada, Lars Iversen, Ulrich Mrowietz, Mark Lebwohl, Maggie Wang, Veerle Vanvoorden, Eva Cullen, Fabienne Staelens, Kim A. Papp
- 27394 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial
- Amy S. Paller, Stephan Weidinger, Michael J. Cork, Danielle Marcoux, Norito Katoh, Haixin Zhang, Ana B. Rossi, Brad Shumel, Annie Zhang, Randy Prescilla, Jingdong Chao
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?